Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics Guidance for Industry December 2018

GUIDANCE DOCUMENT

• Docket Number: FDA-2005-D-0225
• Issued by: Oncology Center of Excellence; Center for Biologics Evaluation and Research; Center for Drug Evaluation and Research

This guidance provides recommendations to applicants on endpoints for cancer clinical trials submitted to the Food and Drug Administration (FDA) to support effectiveness claims in new drug applications (NDAs), biologics license applications (BLAs), or supplemental applications.   It also provides background information and discusses general regulatory principles.  The endpoints discussed in this guidance are for drugs to treat patients with an existing cancer.   This guidance does not address endpoints for drugs to prevent or decrease the incidence of cancer.

This guidance is a revision of the final guidance of the same title that published in May 2007.  This guidance replaces the May 2007 guidance of the same title.  

In general, FDA’s guidance documents do not establish legally enforceable responsibilities.  Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited.  The use of the word should in Agency guidances means that something is suggested or recommended, but not required.

---

Submit Comments

Submit Comments Online

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2005-D-0225.